Elective regional lymph node dissection in cutaneous melanoma

References

• Balch C M., Soong S, Murad T M., et al. Multifactorial analysis of melanoma III. Prognostic factors in patients with regional lymph node metastases. (Stage II). Ann Surg 1981; 193: 377–88
   PubMed Web of Science ®Google Scholar
• Rigel D S., Friedman R J., Kopf A W., et al. Factors influencing survival in melanoma. Dermatol Clin 1991; 9(4)631–42
   PubMed Web of Science ®Google Scholar
• Bevilaqua R G., Coit D G., Rogatko A, et al. Axillary dissection in melanoma. Prognostic variables in node positive patients. Ann Surg 1990; 212(2)125–31
   PubMed Web of Science ®Google Scholar
• McCarthy W H., Shaw H M., Cascinelli N, et al. Elective lumph node dissection for melanoma: two prospectives. World J Surg 1992; 16(2)203–13
   PubMed Web of Science ®Google Scholar
• Balch C M. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 1988; 6(1)163–72
   PubMed Web of Science ®Google Scholar
• Cady B. ‘Prophylactic’ lymph node dissection in melanoma: Does it help?. J Clin Oncol 1988; 6(1)2–4
   PubMed Web of Science ®Google Scholar
• Balch C M., Cascinelli N, Milton G W., . Elective lymph node dissection: pros and cons. Cutaneous melanoma, clinical management and treatment results worldwide, C M. Balch, G W. Milton, et al. J.B. Lippincott, Philadelphia 1985; 131–57
   Google Scholar
• Ingvar C, Erichsen C, Johnsson P. Morbidity following prophylactic and therapeutic lymph node dissection-a comparison. Tumori 1984; 70: 529–33
   PubMed Web of Science ®Google Scholar
• Callery C, Cochran A J., Rose D J., et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. Ann Surg 1982; 196: 69–75
   PubMed Web of Science ®Google Scholar
• Olson R M., Woods J E., Soule E H. Regional lymph node management and outcome in 100 patients with head and neck melanoma. Am J Surg 1981; 142: 470–3
   PubMed Web of Science ®Google Scholar
• Coit D G., Rogatko A, Brennan M F. Prognostic factors in patients with melanoma metastatic to axillary or inguinal nodes. A multivariate analysis. Ann Surg 1991; 214(5)627–36
   PubMed Web of Science ®Google Scholar
• Morton D L., Wanek L, Nizze J A., et al. Improved long term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991; 214: 491–9
   PubMed Web of Science ®Google Scholar
• Kissin M W., Simpson D A., Easton D. Prognostic factors related to survival and groin recurrence following therapeutic lymph node dissection for lower limb melanoma. Cancer 1990; 66: 2522–7
   PubMedGoogle Scholar
• Day C L., Sober A J., Lew R A., et al. Malignant melanoma with positive nodes and relatively good prognoses: micro-staging retains prognostic significance in clinical stage I patients with metastases to regional nodes. Cancer 1981; 47: 955–62
   PubMed Web of Science ®Google Scholar
• Koh H K., Sober A J., Day C L., et al. Prognosis of clinical stage I melanoma patients with positive elective regional node dissection. J Clin Oncol 1986; 4: 1238–44
   PubMed Web of Science ®Google Scholar
• Veronesi U, Adamus J, Bandiera D C., et al. Stage I melanoma of the limbs. Immediate versus delayed node dissection. Tumori 1980; 66: 373–96
   PubMed Web of Science ®Google Scholar
• Cochran A J., Pihl E, Wen D R., et al. Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunologic studies. J Natl Cancer Inst 1987; 98: 399–405
   Google Scholar
• Fisher B, Saner E, Fisher E R. Studies concerning the regional lymph node in cancer IV: Tumor inhibition by regional lymph node cells. Cancer 1974; 33: 631–6
   PubMed Web of Science ®Google Scholar
• Fisher B. Tumors. Surg Gynecol Obstet 1973; 136: 216–19
   PubMedGoogle Scholar
• Reiss C K., Volenec F J., Humphrey M, et al. The role of the regional lymph node in breast cancer: a comparison between nodal and systemic reactivity. J Surg Oncol 1983; 22: 249–53
   PubMed Web of Science ®Google Scholar
• Barna B P., Deodhar S D. Immunologic activity of regional lymph nodes in tumor bearing mice. Cancer Res 1979; 39: 2711–17
   PubMed Web of Science ®Google Scholar
• Kokoschka E M., Uchida A, Yanagawa E, et al. Spontaneous and natural cytotoxicity in lymph nodes draining primary melanoma. J Invest Dermatol 1983; 80: 368
   Web of Science ®Google Scholar
• Ellis R J., Wernick G, Zabriskie J B., et al. Immunologic competence of regional lymph nodes in patients with breast cancer. Cancer 1975; 35: 655–9
   PubMed Web of Science ®Google Scholar
• Fisher B, Fisher E R. Studies concerning the regional lymph node in cancer II. Maintenance of immunity. Cancer 1972; 29: 1496–501
   PubMed Web of Science ®Google Scholar
• Crile G, Jr. Rationale of simple mastectomy without radiation for clinical stage I cancer of the breast. Surg Gynecol Obstet 1965; 120: 975–82
   PubMedGoogle Scholar
• Pendergrast W J., Soloway M S., Myers G H., et al. Regional lymphadenectomy and tumor immunity. Surg Gynecol Obstet 1976; 142: 385–90
   PubMedGoogle Scholar
• Crile G, Jr. The effect on metastases of removing or irradiating regional lymph nodes of mice. Surg Gynecol Obstet 1968; 126: 1270–2
   PubMedGoogle Scholar
• Crile G, Jr. Possible role of uninvolved regional nodes in preventing metastases from breast cancer. Cancer 1969; 24: 1283–5
   PubMed Web of Science ®Google Scholar
• Berg J W., Huvos A W., Axtell L I., et al. A new sign of favorable prognosis in mammary cancer; hyperplastic reactive lymph nodes in the apex of the axilla. Ann Surg 1973; 177: 8–12
   PubMed Web of Science ®Google Scholar
• Pihl E, Nairn R C., Milne B J., et al. Lymphoid hyperplasia. A major prognostic feature in 519 cases of colorectal carcinoma. Am J Pathol 1980; 100: 469–80
   PubMed Web of Science ®Google Scholar
• Farzad Z, Cochran A J., McBride W H., et al. Lymph node subset alterations in nodes regional to human melanoma. Cancer Res 1990; 50: 3585–8
   PubMed Web of Science ®Google Scholar
• Polk H C., Jr, Bland K I. Routine elective lymph node dissection in melanoma-unnecessary treatment?. Surgical oncology. Controversies in cancer treatment, T X. O'Connell. GK Hall, Boston 1981; 122–36
   Google Scholar
• Silberman A W. Malignant melanoma. Practical considerations concerning regional lymph node dissection. Ann Surg 1987; 206: 206–9
   PubMed Web of Science ®Google Scholar
• Wanebo J H., Fortner J G., Woodruff J, et al. Selection of the optimum surgical treatment of stage I melanoma by depth of microinvasion: use of the combined microstage technique (Clark-Breslow). Ann Surg 1975; 182: 302–15
   PubMed Web of Science ®Google Scholar
• Goldsmith H S. The debate over immediate lymph node dissection in melanoma. Surg Gynecol Obstet 1979; 148: 403–8
   PubMedGoogle Scholar
• Gumport S L., Harris M N. Results of regional lymph node dissection for melanoma. Am Surg 1974; 179: 105–8
   Google Scholar
• Veronesi U, Adamus J, Bandiera D C., et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982; 49: 2420–30
   PubMed Web of Science ®Google Scholar
• Fortner J G., Woodruff J, Shottenfeld D, et al. Biostatistical basis of elective node dissection for malignant melanoma. Ann Surg 1977; 186(1)101–3
   PubMed Web of Science ®Google Scholar
• Veronesi U. Delayed node dissection in stage I malignant melanoma: justification and advantages. Cancer Invest 1987; 5: 47–53
   PubMed Web of Science ®Google Scholar
• McCarthy J G., Haagenson C D., Herter F P. The role of groin dissection in the management of melanoma of the lower extremity. Ann Surg 1974; 179: 156–9
   PubMed Web of Science ®Google Scholar
• Karakousis C P., Emrich L J., Rao U. Groin dissection in malignant melanoma. Am J Surg 1985; 152: 491–5
   Google Scholar
• Urist M M., Maddox W A., Kennedy J E., et al. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer 1983; 51: 2152–6
   PubMed Web of Science ®Google Scholar
• Bowsher W G., Taylor B A., Huges L E. Morbidity, mortality and local recurrence following regional node dissection for melanoma. Br J Surg 1986; 73: 906–8
   PubMed Web of Science ®Google Scholar
• Holmes E C., Moseley H S., Morton D L., et al. A rational approach to the surgical management of melanoma. Ann Surg 1977; 186: 481–90
   PubMed Web of Science ®Google Scholar
• James J H. Lymphoedema following ilio-inguinal lymph node dissection. Scand J Plast Reconstr Surg 1982; 16: 167–71
   PubMed Web of Science ®Google Scholar
• Seigler H F., Fetter B F. Current managment of melanoma. Ann Surg 1977; 186: 1–12
   PubMed Web of Science ®Google Scholar
• Coit D G., Brennan M F. Extent of lymph node dissection in melanoma of the trunk and lower extremity. Arch Surg 1989; 124: 162–6
   PubMedGoogle Scholar
• Karakousis C P. Lymphedema after groin dissection. Am J Surg 1983; 145: 205–8
   PubMed Web of Science ®Google Scholar
• Bland K I., Klamer T W., Polk H C., et al. Isolated regional lymph node dissection. Morbidity, mortality and economic considerations. Ann Surg 1981; 193: 372–6
   PubMed Web of Science ®Google Scholar
• Papachristou D, Fortner J G. Comparison of lymphedema following incontinuity and discontinuity of groin dissection. Ann Surg 1977; 195: 13–16
   Google Scholar
• Baas P C., Koops H S., Hoekstra H J., et al. Groin dissection in the treatment of lower extremity melanoma, short and long term morbidity. Arch Surg 1992; 127: 281–6
   PubMedGoogle Scholar
• Lotze M T., Duncan M A., Gerber L H., et al. Early versus delayed shoulder motion following axillary dissection. Ann Surg 1981; 193: 288–95
   PubMed Web of Science ®Google Scholar
• Byers R M. The role of modified neck dissection in the treatment of cutaneous melanoma of the head and neck. Arch Surg 1986; 121: 1338–41
   PubMedGoogle Scholar
• Balch C M., Urist M M., Maddox W A., . Management of regional metastatic melanoma. Cutaneous melanoma, clinical management and treatment results worldwide, C M. Balch, G W. Milton, et al. J.B. Lippincott, Philadelphia 1985; 93–130
   Google Scholar
• Balch C M. Surgical management of regional lymph nodes in cutaneous melanoma. J Am Acad Dermatol 1980; 3: 511–24
   PubMed Web of Science ®Google Scholar
• Balch C M., Murad T Q., Soong S, et al. Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer 1979; 43: 883–8
   PubMed Web of Science ®Google Scholar
• Veronesi U, Adamus J, Bandiera D C., et al. Inefficacy of immediate lymph node dissection in stage I melanoma of the limbs. N Engl J Med 1977; 297: 627–30
   PubMed Web of Science ®Google Scholar
• Milton G W., Shaw H M., McCarthy W H., et al. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 1982; 69: 108–11
   PubMed Web of Science ®Google Scholar
• Cascinelli N, Preda F, Vaglini M, et al. Metastatic spread of stage I melanoma of the skin. Tumori 1983; 69: 449–54
   PubMed Web of Science ®Google Scholar
• Lane N, Lattes R, Malm J. Clinicopathological correlations in a series of 117 malignant melanomas of the skin of adults. Cancer 1958; 11: 1025–43
   PubMed Web of Science ®Google Scholar
• Cochran A J., Wen D, Morton D L. Occult tumor cells in the lymph nodes of patients with pathologically stage I melanoma. An immunohistochemical study. Am J Surg Pathol 1988; 12(8)612–18
   PubMed Web of Science ®Google Scholar
• Heller R, Becker J, Wasselle J, et al. Detection of occult lymph node metastases in malignant melanoma. Ann Plast Surg 1992; 28(1)74–7
   PubMed Web of Science ®Google Scholar
• Breslow A. Surgical pros and cons. Surg Gynecol Obstet 1979; 149: 731–2
   PubMedGoogle Scholar
• Goldsmith H S. Surgical pros and cons. Surg Gynecol Obstet 1979; 149: 733–4
   PubMedGoogle Scholar
• Rivers J K., Ho V C. Malignant melanoma. Who shall live and who shall die?. Arch Dermatol 1992; 128: 537–42
   PubMed Web of Science ®Google Scholar
• Hansen M G., McCarten A B. Tumor thickness and lymphocytic infiltration in malignant melanoma of the head and neck. Am J Surg 1974; 128: 557–61
   PubMed Web of Science ®Google Scholar
• Edlh J, Boeryd B, Peterson L. Prognostic factors in cutaneous melanoma in stage I. Scand J Plast Reconstr Surg 1978; 12: 243–55
   PubMedGoogle Scholar
• Balch C M., Murad T M., Soong S J., et al. A multifactorial analysis of melanoma: prognostic histopathologic features comparing Clark's and Breslow's staging methods. Ann Surg 1978; 188: 732–42
   PubMed Web of Science ®Google Scholar
• Breslow A. Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg 1975; 182: 572–5
   PubMed Web of Science ®Google Scholar
• Geelhoed G W., Breslow A, McCune W S. Malignant melanoma: correlation of long-term follow-up with clinical staging, level of invasion and thickness of the primary tumor. Am Surg 1977; 43: 77–85
   PubMed Web of Science ®Google Scholar
• McCarthy W H., Shaw H M., Milton G W. Efficacy of elective lymph node dissection in 2,347 patients with clinical stage I malignant melanoma. Surg Gynecol Obstet 1985; 161: 575–80
   PubMedGoogle Scholar
• Biess B, Broker E B., Drepper H, et al. Should elective lymph node dissection be used for treatment of primary melanoma?. J Cancer Res Clin Oncol 1989; 115: 470–3
   PubMed Web of Science ®Google Scholar
• Cox D R. Regression model and life tables. J R Stat Soc Br 1972; 34: 187–220
   Web of Science ®Google Scholar
• Lew R A., Day C L., Harrist T J., et al. Multivariate analysis. Some guidelines for physicians. JAMA 1983; 249: 641–3
   PubMed Web of Science ®Google Scholar
• Balch C M., Soong S J., Murad T M., et al. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 1979; 86: 343–51
   PubMed Web of Science ®Google Scholar
• Urist M M., Balch C M., Soong S J., et al. Head and neck melanoma in 534 clinical stage I patients. Ann Surg 1984; 200: 769–75
   PubMed Web of Science ®Google Scholar
• Balch C M., Soong S J., Milton G W., et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA and New South Wales, Australia. Ann Surg 1982; 196: 677–84
   PubMed Web of Science ®Google Scholar
• Reintgen D S., Cox E B., McCarthy K S., et al. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 1983; 198: 379–85
   PubMed Web of Science ®Google Scholar
• Day C L., Mihm M C., Sober A L., et al. Prognostic factors for melanoma patients with lesions 0.76–1.69 mm in thickness. An appraisal of 'thin' level IV lesions. Ann Surg 1982; 195: 30–4
   PubMed Web of Science ®Google Scholar
• Day C L., Mihm M C., Lew R A., et al. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51–3.99 mm). A conceptual model for tumor growth and metastasis. Ann Surg 1982; 195: 35–43
   PubMed Web of Science ®Google Scholar
• Day C L., Lew R A., Mihm M C., et al. A multivariate analysis of prognostic factors for melanoma patients with lesions 3.65 mm in thickness. The importance of alternate Cox models. Ann Surg 1982; 195: 44–9
   PubMed Web of Science ®Google Scholar
• Elder D E., Guerry D, Van Horn M, et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51–3.99). Cancer 1985; 56: 413–18
   PubMed Web of Science ®Google Scholar
• Blois M S., Sagebiel R W., Tuttle M S., et al. Judging prognosis in malignant melanoma of the skin. A problem of inference over small data bases. Ann Surg 1983; 198: 200–6
   PubMed Web of Science ®Google Scholar
• Day C L., Lew R A. Malignant melanoma prognostic factors 7, elective lymph node dissection. J Dermatol Surg Oncol 1985; 11: 233–9
   PubMedGoogle Scholar
• Sim F H., Taylor W F., Pritchard D I., et al. Lymphadenectomy in the management of stage I malignant melanoma: A prospective, randomized study. Mayo Clin Proc 1986; 61: 697–705
   PubMed Web of Science ®Google Scholar
• Adams C M., Giltman L I. Elective lymph node dissection in stage I melanoma-necessary or not?. Am Surg 1985; 51: 504–7
   PubMed Web of Science ®Google Scholar
• Stankard C, Cruse C W., Cox C, et al. The concept of lymph node dissections in patients with malignant melanoma. Ann Plast Surg 1992; 28(1)33–8
   PubMed Web of Science ®Google Scholar
• Sim F H., Taylor W F., Ivina J C., et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in the management of malignant melanoma: preliminary results. Cancer 1979; 41: 948–56
   Web of Science ®Google Scholar
• Pritchard D J., Sim F H. Surgical management of malignant melanoma of the trunk and extremities. Mayo Clin Proc 1989; 64: 846–51
   PubMed Web of Science ®Google Scholar
• Keenan A M. Immunolymphoscintigraphy. Semin Nucl Med 1989; 19(4)322–31
   PubMed Web of Science ®Google Scholar
• Blend M J., Roman S G., Salk D J., et al. Role of technetium 99m-labeled monoclonal antibody in the management of melanoma patients. J Clin Oncol 1992; 10(8)1330–7
   PubMed Web of Science ®Google Scholar
• Frytak S, Creagan E T., Brown M L., et al. A technetium-labeled monoclonal antibody for imaging metastatic melanoma. Am J Clin Oncol 1991; 14(2)156–61
   PubMed Web of Science ®Google Scholar
• Morton D L., Wen D R., Wong J H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392–9
   PubMed Web of Science ®Google Scholar
• Cochran A J., Wen D R., Morton D L. Management of the regional lymph nodes in patients with cutaneous malignant melanoma. World J Surg 1992; 16(2)214–21
   PubMed Web of Science ®Google Scholar
• Berman C G., Norman J, Cruse C W., et al. Lymphoscintigraphy in malignant melanoma. Ann Plast Surg 1992; 28(1)29–32
   PubMed Web of Science ®Google Scholar
• Reintgen D S., Sullivan D, Coleman E, et al. Lymphoscin-tigraphy for malignant melanoma. Implications for surgery. Am Surg 1983; 49: 672–8
   PubMedGoogle Scholar
• Logic J R., Balch C M. Defining lymphatic drainage patterns with cutaneous lymphoscintigraphy. Cutaneous melanoma, clinical management and treatment results worldwide, C M. Balch, G W. Milton. J.B. Lippincott, Philadelphia 1985; 159–70
   Google Scholar
• Reintgen D S., Cruse C W., Wells K E., et al. Isolated limb perfusion for recurrent melanoma of the extremity. Ann Plast Surg 1992; 28(1)50–4
   PubMed Web of Science ®Google Scholar
• Santinami M, Belli F, Cascinelli N, et al. Seven years' experience with hyperthermic perfusions in extracorpreal circulation for melanoma of the extremity. J Surg Oncol 1989; 42: 201–8
   PubMed Web of Science ®Google Scholar
• Stehlin J S. Hyperthermic perfusion with chemotherapy for cancer of the extremities. Surg Gynecol Obstet 1969; 129: 305–8
   PubMedGoogle Scholar
• Oldhoff H M., Koops H S. Regional perfusion in the treatment of patients with locally metastasized malignant melanoma of the limbs. Eur J Cancer 1981; 17(4)471–6
   PubMed Web of Science ®Google Scholar
• Storm F K., Morton D L. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg 1985; 150: 32–5
   PubMed Web of Science ®Google Scholar
• Lienard D, Lejeune F J., Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon gamma and melphalan in isolation perfusion. World J Surg 1992; 16: 234–40
   PubMed Web of Science ®Google Scholar
• Krementz R T., Carter R D., Sutherland C M., et al. Chemotherapy by regional perfusion for limb melanoma. Am Surg 1987; 53: 133–40
   PubMed Web of Science ®Google Scholar
• Skene A I., Bulman A S., Williams T R., et al. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 1990; 77: 765–7
   PubMed Web of Science ®Google Scholar
• Wong J H., Gagle L A., Kopald K H., et al. Natural history and selective management of in transit melanoma. J Surg Oncol 1990; 44: 146–50
   PubMed Web of Science ®Google Scholar
• Muchmore J H., Krementz E T., Cater R D., et al. Isolated regional perfusion for treatment of limb melanoma in the American black. Am Surg 1989; 55: 232–7
   PubMed Web of Science ®Google Scholar
• Koops H S., Kroon B B., Oldhoff J, et al. Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of the extremities. World J Surg 1992; 16: 241–5
   PubMed Web of Science ®Google Scholar
• McBride C M., Sugarbaker E V., Hickey R C. Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs. Ann Surg 1975; 182: 316–24
   PubMed Web of Science ®Google Scholar
• Rege V B., Leona L A., Soderberg C H., et al. Hyperthermic adjuvant perfusion chemotherapy for stage I malignant melanoma of the extremity with literature review. Cancer 1983; 52: 2033–9
   PubMed Web of Science ®Google Scholar
• Fletcher J R., White C R., Fletcher W S. Improved survival rates of patients with acral lentiginous melanoma treated with hyperthermic isolation perfusion, wide excision, and regional lymphadenectomy. Am J Surg 1986; 151: 593–8
   PubMed Web of Science ®Google Scholar
• Edwards M J., Boddie A W., Ames F C., et al. Isolated limb perfusion for stage I melanoma of the extremity: a comparison of melphalan and dacarbazine (DTIC). South Med J 1989; 82(8)985–7
   PubMed Web of Science ®Google Scholar
• Ghussen F, Nagel K, Groth W, et al. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Am Surg 1984; 200(6)764–8
   Google Scholar
• Ghussen F, Kruger I, Groth W, et al. The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 1988; 1: 654–9
   Google Scholar
• Edwards M J., Soong S J., Boddie A W., et al. Isolated limb perfusion for localized melanoma of the extremity. Arch Surg 1990; 125: 317–21
   PubMed Web of Science ®Google Scholar
• Golomb F M., Bromberg J, Dubin N. A controlled study of the survival experience of patients with primary malignant melanoma of the distal extremities treated with adjuvant isolated perfusion. Adjuvant Ther Cancer 1979; 2: 519–26
   Google Scholar
• Thompson J F., Gianoutsos M P. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992; 16: 227–33
   PubMed Web of Science ®Google Scholar
• Lienard D, Ewalenko P, Delmotte J, et al. High dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10(1)52–60
   PubMed Web of Science ®Google Scholar
• Coit D J. Hyperthermic isolation limb perfusion for malignant melanoma: a review. Cancer Invest 1992; 10(4)277–84
   PubMed Web of Science ®Google Scholar
• Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989; 63: 2551–61
   PubMed Web of Science ®Google Scholar
• Hafstrom L, Rudenstam C, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol 1991; 9: 2091–4
   PubMed Web of Science ®Google Scholar
• Franklin H R., Koops H S., Oldhoff J, et al. To perfuse or not perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol 1988; 6: 701–8
   PubMed Web of Science ®Google Scholar
• Singluff C L., Vollmer R T., Reintgen D S., et al. Lethal “thin” malignant melanoma. Am Surg 1988; 208(2)150–61
   Google Scholar
• Gilchrest K W., Gilbert E, Metier G. Importance of microscopic vascular invasion in primary cutaneous malignant melanoma. Surg. Gynecol Obstet 1977; 145: 559–61
   Google Scholar
• McGovern V J., Murad T M. Pathology of melanoma, an overview. Cutaneous melanoma, clinical management and treatment results worldwide, C M. Balch, G W. Milton. J.B. Lippincott, Philadelphia 1985; 29–53
   Google Scholar
• Harrist T J., Rigel D S., Day C L., et al. Microscopic satellites are more highly associated with regional lymph node metastasis than is primary melanoma thickness. Cancer 1984; 53: 2183–7
   PubMed Web of Science ®Google Scholar
• Day C L., Harrist T J., Gorstein F, et al. Malignant melanoma. The prognostic significance of “microscopic satellites” in the reticular dermis and subcutaneous fat. Ann Surg 1981; 194: 108–12
   PubMed Web of Science ®Google Scholar
• Roman S G., Han M C., Das Gupta T K. Histologic prognostic indicators in cutaneous malignant melanoma. Semin Oncol 1988; 15(6)558–65
   PubMed Web of Science ®Google Scholar
• Balch C M., Wilkerson J A., Murad T Q., et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980; 45: 3012–17
   PubMed Web of Science ®Google Scholar
• McGovern V J., Shaw H M., Müton G W., et al. Ulceration and prognosis in cutaneous malignant melanoma. Histopathology 1982; 6: 399–407
   PubMed Web of Science ®Google Scholar
• Van der Esch E P., Cascinelli N, Predal F, et al. Stage I melanoma of the skin: evaluation of prognosis according to histologic characteristics. Cancer 1981; 48: 1668–73
   PubMed Web of Science ®Google Scholar
• Shaw H M., McCarthy W H., McCarthy S W., et al. Thin malignant melanomas and recurrence potential. Arch Surg 1987; 122: 1147–50
   PubMedGoogle Scholar
• Schneebaum S, Briele H A., Walker M J., et al. Cutaneous thick melanoma. Prognosis and treatment. Arch Surg 1987; 122: 707–11
   PubMedGoogle Scholar